Multiscale and multi-modal insights into drug formulation - free webinar
07 September 2021 - 07 September 2021
The majority of pharmaceutical powders require a size <500 µm for ease of manufacture and biopharmaceutical performance. Powder behaviour of particles in this size-range spans cohesive to aeratable powders. Powder performance is dependent on the powder bulk density and micromeritic properties of individual particles, but also crucially the structuring of particles within the powder bed. Micromeritic assessment is also routinely performed using image analysis or particle sizing techniques such as laser diffraction analysis. However, there is a clear need for techniques that provide non-destructive granular information of pharmaceutical powder structures.
Formulation equivalence between different batches of products or between comparator innovator and generic products has emerged as a hot topic of consideration in regulatory science. Microstructural equivalence (Q3) for powder products is complex, and particularly in the case of Dry Powder Inhalation (DPI) formulations. It is in the characterization of the bulk powder that microstructural assessment is a particular challenge. Current methods for measuring critical material attributes such as the particle size and shape suffer from low resolution, image in 2D or make shape assumptions.
In this webinar, we will present some new approaches using X ray Microscopy (XRM) from nano- to micro-scale that can be utilized for characterizing inhalation powder blends non-destructively to obtain fully 3D information on particle size and shape, its distributions, and powder bed packing. Novel methodologies developed to identify individual chemical phases within blends, their crystal orientations and interactions in 3D will also be presented. The results show the promise for XRM as a valuable powder characterisation technique that develops our fundamental understanding of powder microstructure, and microstructural descriptors for the United States Food and Drug Administration Q3 microstructural assessments.
Virtual Conference
http://www.drug-formulation-zeiss-webinar.com/DDTwl
Pre-filled Syringes San Francisco 2021
13 September 2021 - 14 September 2021
As part of SMi’s leading Injectables series, this year’s event will address the key drivers of the pre-filled syringes and combination products industry to give a comprehensive insight into the latest device innovations, regulatory updates and future insights for the coming year. With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, the field is evolving at an exponential rate with connectivity and digital health strategies for devices and studies at the forefront. Furthermore, this event will delve into the key takeaways following the global pandemic and discover how this will be used to enhance future drug delivery device development.
This comprehensive overview will explore the changing global market and latest innovations in device design and development for injectable drug delivery. Case studies from leading industry and regulatory experts will explore platform approaches for combination products, enhanced device design and usability considerations, change management and compatibility for novel drug products.
The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
Hyatt Centric Fisherman's Wharf, San Francisco (Virtual Attendance Option Available)
http://www.prefilled-sanfrancisco.com/oddwl
SMi’s Aseptic Processing Conference
20 September 2021 - 21 September 2021
The aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs, pragmatic barrier system applications, adaptability and modularity in fill finish, robotics and automation, small and agile product manufacturing, just to name a few. In 2018, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027, with a CAGR growth of 9.18%.
The industry is ever changing and with the advent of innovative therapeutics taking hold, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster.
Join us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing.
London, UK - (Virtual Attendance Option Available)
http://www.asepticprocessing.co.uk/drugdistodayWL
Oligonucleotide Therapeutics and Delivery Conference 2021
22 September 2021 - 23 September 2021
On the way to maximising the potential of oligo-based medicine
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.
SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions.
Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.
Holiday Inn Kensington Forum, London (Virtual Attendance Option Available)
http://www.oligonucleotide.co.uk/DDTwl